Innate Pharma : IPH4102 set to enter into phase II in H1 2019
>Phase 1 results which encourage a phase II - Innate Pharma published new data Monday evening at the ASH congress (American Society of Hematology) from its phase 1 trial with IPH4102 for patients with Sézary's syndrome (SS) - a rare type of cutaneous T-cell lymphoma (CTCL - approximately 6,000 patients per year in the US and Europe).This cancer is characterised by infiltration of malignant LT into the skin and a five-year survival rate of about 10%, it is usually diag...Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.